United Kingdom

Britain approves GSK-Vir antibody-based COVID-19 treatment

1 minute read

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Dec 2 (Reuters) - Britain's drug regulator on Thursday approved GSK (GSK.L) and Vir Biotechnology's (VIR.O) antibody based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.

The approval comes as GSK separately announced the treatment has shown to work against the Omicron variant.

Register now for FREE unlimited access to Reuters.com
Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters